New Approaches in Educational Management and Health Sciences

New Approaches in Educational Management and Health Sciences

The effect of Rifampicin on cells in the CA2 and CA3 regions of the hippocampus of male Wistar rats of ischemia model

Document Type : Original Article

Authors
Behnood Avand Amini 1
Zahra Nadia Sharifi 2
Shabnam Movassaghi 2
Parivash Davoudi 3
1 Department of Anatomical Sciences & Cognitive Neuroscience, TeMS.C., Islamic Azad University, Tehran, Iran
2 Department of Anatomical Sciences & Cognitive Neuroscience, TeMS.C., Islamic Azad University, Tehran, Iran; Herbal Pharmacology Research Center, TeMS.C., Islamic Azad University, Tehran, Iran
3 Department of Anatomical Sciences & Cognitive Neuroscience, TeMS.C., Islamic Azad University, Tehran, Iran
10.22034/edus.2025.565827.1075
Abstract
Introduction: Cerebral ischemia is a major global problem. Certain areas of the brain and certain types of neurons, including hippocampal pyramidal neurons, are more sensitive to cerebral ischemia. Rifampicin is an antibiotic that has recently been considered as a neuroprotector. Studies have reported that this drug has a neurotrophic effect on neurons. In this study, the neurotrophic effect of rifampicin in the CA2 and CA3 regions of the hippocampus following cerebral ischemia/reperfusion was investigated.
Materials and Methods: Male Wistar rats were randomly divided into 4 groups of 6: control, ischemic, experimental, and vehicle. Rifampicin was injected intraperitoneally at a dose of 20 mg/kg 20 minutes after ischemia and 24 hours after reperfusion. Ischemia was induced by bilateral occlusion of the common carotid arteries for 20 minutes. Four days later, all rats were sacrificed and the CA2 and CA3 hippocampal regions were examined by Nissl staining.
Results: The results showed that induction of ischemia cannot cause the loss of neurons in the CA2 region, but ischemia was able to cause a significant decrease in the number of pyramidal cells in the CA3 region of the hippocampus. A significant difference was observed between the number of pyramidal cells in the CA3 region of the hippocampus in the ischemic and control groups, while this difference was not significant between the control and drug groups.
Conclusion: Rifampicin has a neurotrophic effect and prevents the death of neurons in the CA3 region of the hippocampus following transient global ischemia/reperfusion.
Keywords
Rifampicin
Cerebral Ischemia
Hippocampus

Ethics Approval ID: IR.IAU.TMU.REC.1397.335

 

1.         Billig AJ, Lad M, Sedley W, Griffiths TD. The hearing hippocampus. Prog Neurobiol. 2022;218:102326. doi: 10.1016/j.pneurobio.2022.102326
2.         Zhao Y, Zhang X, Chen X, Wei Y. Neuronal injuries in cerebral infarction and ischemic stroke: From mechanisms to treatment (Review). Int J Mol Med. 2022;49(2):15. doi: 10.3892/ijmm.2021.5070
3.         Yu L, Zhang Y, Chen Q, He Y, Zhou H, Wan H, Yang J. Formononetin protects against inflammation associated with cerebral ischemia-reperfusion injury in rats by targeting the JAK2/STAT3 signaling pathway. Biomed Pharmacother. 2022;149:112836. doi: 10.1016/j.biopha.2022.112836
4.         Abdulazim A, Heilig M, Rinkel G, Etminan N. Diagnosis of Delayed Cerebral Ischemia in Patients with Aneurysmal Subarachnoid Hemorrhage and Triggers for Intervention. Neurocrit Care. 2023;39(2):311-319. doi: 10.1007/s12028-023-01812-3
5.         Slotnick SD. The hippocampus and long-term memory. Cogn Neurosci. 2022;13(3-4):113-114. doi: 10.1080/17588928.2022.2128736
6.         S Lang M, Colby S, Ashby-Padial C, Bapna M, Jaimes C, Rincon SP, Buch K. An imaging review of the hippocampus and its common pathologies. J Neuroimaging. 2024;34(1):5-25. doi: 10.1111/jon.13165
7.         Rolls ET. The hippocampus, ventromedial prefrontal cortex, and episodic and semantic memory. Prog Neurobiol. 2022;217:102334. doi: 10.1016/j.pneurobio.2022.102334
8. Tarasek D, Wojtasek H. Rifampicin is not an inhibitor of tyrosinase. Int J Biol Macromol. 2022;216:830-835. 10.1016/j.ijbiomac.2022.07.217
9. Cao Y, Wang T, He K, Xue J, Wang X, Liang J. High-dose rifampicin for the treatment of tuberculous meningitis: a meta-analysis of randomized controlled trials. J Clin Pharm Ther. 2022;47(4):445-454. doi: 10.1111/jcpt.13555
10. Barzegari A, Amouzad Mahdirejei H, Hanani M, Esmaeili MH, Salari AA. Adolescent swimming exercise following maternal valproic acid treatment improves cognition and reduces stress-related symptoms in offspring mice: Role of sex and brain cytokines. Physiol Behav. 2023;269:114264. doi: 10.1016/j.physbeh.2023.114264
11. Felker I, Trajman A. Shorter regimens for multidrug-/rifampicin-resistant TB. Int J Tuberc Lung Dis. 2023;27(1):3-4. doi: 10.5588/ijtld.22.0537
12. van Ingen J, Hoefsloot W, Dartois V, Dick T. Rifampicin has no role in treatment of Mycobacterium avium complex pulmonary disease and bactericidal sterilising drugs are needed: a viewpoint. Eur Respir J. 2024;63(5):2302210. doi: 10.1183/13993003.02210-2023
13. Lan X, Wang Q, Liu Y, You Q, Wei W, Zhu C, et al. Isoliquiritigenin alleviates cerebral ischemia-reperfusion injury by reducing oxidative stress and ameliorating mitochondrial dysfunction via activating the Nrf2 pathway. Redox Biol. 2024;77:103406. doi: 10.1016/j.redox.2024.103406
14. Amouzad Mahdirejei H, Fadaei Reyhan Abadei S, Abbaspour Seidi A, Eshaghei Gorji N, Rahmani Kafshgari H, Ebrahim Pour M, Bagheri Khalili H, et al. Effects of an eight-week resistance training on plasma vaspin concentrations, metabolic parameters levels and physical fitness in patients with type 2 diabetes. Cell J. 2014;16(3):367-74. doi: PMC4204186
15. Dietz RM, Dingman AL, Herson PS. Cerebral ischemia in the developing brain. J Cereb Blood Flow Metab. 2022;42(10):1777-1796. doi: 10.1177/0271678X221111600
16. Baranovicova E, Kalenska D, Kaplan P, Kovalska M, Tatarkova Z, Lehotsky J. Blood and Brain Metabolites after Cerebral Ischemia. Int J Mol Sci. 2023;24(24):17302. doi: 10.3390/ijms242417302
17. Barzegari A, Amouzad Mahdirejei H. Effects of 8 weeks resistance training on plasma vaspin and lipid profile levels in adult men with type 2 diabetes. Caspian J Intern Med. 2014;5(2):103-8. doi: PMC3992237
18. Baranovicova E, Kalenska D, Kaplan P, Kovalska M, Tatarkova Z, Lehotsky J. Blood and Brain Metabolites after Cerebral Ischemia. Int J Mol Sci. 2023;24(24):17302. doi: 10.3390/ijms242417302
19. Vaezipour N, Bigi S, Song R, Ritz N. Rifampicin and its neuroprotective properties in humans - A systematic review. Biomed Pharmacother. 2025;185:117928. doi: 10.1016/j.biopha.2025.117928
20. Bolleddula J, Gopalakrishnan S, Hu P, Dong J, Venkatakrishnan K. Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug-drug interaction studies. Clin Transl Sci. 2022;15(9):2075-2095. doi: 10.1111/cts.13357
21. Amouzad Mahdirejei H, Peeri M, Azarbayjani MA, Masrour FF. Diazepam and exercise training combination synergistically reduces lipopolysaccharide-induced anxiety-like behavior and oxidative stress in the prefrontal cortex of mice. Neurotoxicology. 2023;97:101-108. doi: 10.1016/j.neuro.2023.06.004
22. Wang C, Wu Z, Jiang H, Shi Y, Zhang W, Zhang M, Wang H. Global prevalence of resistance to rifampicin in Mycobacterium leprae: A meta-analysis. J Glob Antimicrob Resist. 2022;31:119-127. doi: 10.1016/j.jgar.2022.08.021
23. Mahdirejei HA, Peeri M, Azarbayjani MA, Fattahi Masrour F. Fluoxetine combined with swimming exercise synergistically reduces lipopolysaccharide-induced depressive-like behavior by normalizing the HPA axis and brain inflammation in mice. Pharmacol Biochem Behav. 2023;232:173640. doi:10.1016/j.pbb.2023.173640
24. Krizsan G, Sallai I, Veres DS, Prinz G, Szeker D, Skaliczki G. Rifampicin resistance and risk factors associated with significantly lower recovery rates after two-stage revision in patients with prosthetic joint infection. J Glob Antimicrob Resist. 2022;30:231-236. doi: 10.1016/j.jgar.2022.06.020
New Approaches in Educational Management and Health Sciences
Volume 2, Issue 4
January 2026
Winter 2026
Pages 55-65

  • Receive Date 02 September 2025
  • Revise Date 24 October 2025
  • Accept Date 01 December 2025